Publications by authors named "Tina Laga"
Article Synopsis
- Circulating cell-free DNA (cfDNA) is being studied as a noninvasive marker for cancer detection, and understanding its origins could enhance cancer diagnosis and treatment management.* -
- The researchers created MetDecode, a deconvolution algorithm that identifies cancer tissue origins using DNA methylation patterns, and built a reference atlas from existing data for various cancers.* -
- MetDecode showed high accuracy, correctly identifying tissue origins in 84.2% of plasma cfDNA samples from cancer patients, and can be accessed online for further use.*
Background: The PAOLA-1/ENGOT-ov25 trial showed improved progression-free (PFS) and overall survival (OS) in homologous recombination deficient (HRD) positive patients treated with olaparib, but not when HRD negative (HRD tested with MyChoice CDx PLUS [Myriad test]).
Patients And Methods: The academic Leuven HRD test consists of capture-based targeted sequencing of genome-wide single-nucleotide polymorphisms and coding exons of eight HR genes including BRCA1, BRCA2, and TP53. We compared the predictive value of the Leuven HRD versus Myriad HRD test for PFS and OS in the randomised PAOLA-1 trial.
Purpose Of Review: Ovarian cancer (OC) is a heterogeneous disease and a mounting body of evidence shows that a 'one-size-fits-all' approach is obsolete. Differences in epidemiology, tumor biology, genetic profiles and treatment responses of these different types necessitate a tumor and patient-specific approach. Ninety percentage consists of epithelial OC with 70% being high-grade serous OC.
View Article and Find Full Text PDFObjective: The aim of this study was to assess the safety and feasibility of macroscopically complete (R0) secondary debulking surgery (SDS) in a single-center cohort of patients with recurrent ovarian cancer. The performances of existing prediction models (DESKTOP score, Tian model) for R0 SDS were evaluated in this cohort.
Methods: Patient, disease, and treatment characteristics of 102 patients undergoing SDS for recurrent ovarian cancer at the University Hospitals Leuven between 1997 and 2014 were collected.